Jonah Feldman on Muck Rack

Jonah Feldman

East Brunswick, New York
As seen in: MJH Life Sciences, OncLive, The Mary Sue, NewsBreak, The Michigan Daily, American Journal of Managed Care, ONCOLOGY journal, CURE Magazine, Contemporary OB/GYN, Targeted Oncology, Urology Times, Oncology Nursing News and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonah

Contact Jonah, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

May 2026 Michigan legislative roundup: Voting Rights Act, chemical weapons ban and restrictions on digital workplace communications

|
By Jonah Feldman
| The Michigan Daily
Each month, The Michigan Daily publishes a compilation of bills in the Michigan Legislature for students at the University of Michigan to know about. The following article explains five bills that have been introduced, passed or signed into law by the Michigan Legislature or Gov. Gretchen Whitmer throughout the month of May 2026. 1.
Open in Who Shared Issue with article?

ASCO 2026: Dynamic Therapy Interventions With PSMA in Metastatic HSPC

|
By Praful Ravi, Russ Conroy, Jonah Feldman
| ONCOLOGY journal
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the intersection of biochemical response and advanced imaging emerged as a critical frontier in refining therapy for metastatic hormone-sensitive prostate cancer (HSPC).
Open in Who Shared Issue with article?

Camizestrant Extends PFS and PFS2 in ESR1-Mutated Advanced Breast Cancer

|
By Ariana Pelosci , Russ Conroy, Jonah Feldman
| ONCOLOGY journal
The final progression-free survival 2 (PFS2) results from the phase 3 SERENA-6 trial (NCT04964934), demonstrating that proactively switching to camizestrant upon detection of emergent ESR1 mutations in patients receiving a first-line aromatase inhibitor (AI) plus CDK4/6 inhibitor (CDK4/6i) extended PFS by a median of 7.6 months compared with continuing the same AI-based regimen.1 In the primary end point analysis, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual...
Open in Who Shared Issue with article?
See all 95 licensed articles (724 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Jonah

Contact Jonah, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified